[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100582596":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":32,"locations":26,"responsibleParty":41,"collaborators":26,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":26,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":53,"maxAge":26,"enrollmentInfo":54,"targetDuration":26,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":72,"whyStopped":26,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":26},{"fullName":5,"class":6},"Medical University of Vienna","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group A - Control Group with only dietological measures","ACTIVE_COMPARATOR","Patients seeking bariatricsurgery will recieve the standard dietological measures to prepare for bariatric surgery for 6 months",[13],"Behavioral: Dietologic measures and lifestyle optimization for weight loss",{"label":15,"type":16,"description":17,"interventionNames":18},"Group B - Intervention with additional Liraglutide","EXPERIMENTAL","Patients seeking bariatricsurgery will recieve the standard dietological measures and additional Liraglutide to prepare for bariatric surgery for 6 months",[19],"Drug: Liraglutide daily (0.6-3.0mg, highest tolerable dose) additional to dietological measures and lifestyle optimization suggestions",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Liraglutide daily (0.6-3.0mg, highest tolerable dose) additional to dietological measures and lifestyle optimization suggestions","Liraglutide daily (0.6-3.0mg, highest tolerable dose) as additional preoperative method for weight loss",[15],null,{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":26},"BEHAVIORAL","Dietologic measures and lifestyle optimization for weight loss","all subjects will receive dietary measures and lifestyle opitmization suggestions in order to drop weight preoperatively.",[9],[33,38],{"name":34,"role":35,"phone":36,"phoneExt":26,"email":37},"Lea Pedarnig, MD","CONTACT","0043014040056210","lea.pedarnig@meduniwien.ac.at",{"name":39,"role":35,"phone":36,"phoneExt":26,"email":40},"Moritz Felsenreich, Ap.Prof.Priv.-Doz.DDr.","moritz.felsenreich@meduniwien.ac.at",{"type":42,"investigatorFullName":43,"investigatorTitle":44,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Daniel Moritz Felsenreich","Professor (Ap. Prof. Priv. Doz. DDr. )","100582596","phase-4-preoperative-use-of-liraglutide-additionally-to-common-dietological-measures-as-opposed-to-dietological-measures-alone-100582596",false,"NCT06865365","Preoperative Use of Liraglutide Additionally to Common Dietological Measures as Opposed to Dietological Measures Alone","Prospective, Randomized, Controlled Trial of Preoperative Use of Saxenda (Liraglutide) Additionally to Common Dietological Measures as Opposed to Dietological Measures Alone","Inclusion Criteria:\n\n\\- Patients seeking bariatric surgery\n\n* BMI \\> 35.0 kg\u002Fm2\n* Health insurance via Österreichische Gesundheitskasse\n* Willingness to be assigned to either of the two groups\n* Willingness to adhere to preoperative dietological measures\n* Follow-up anticipation with blood draws and body weight scans using Secca scale\n* Written informed consent\n\nExclusion Criteria:\n\n* Patients with previous bariatric surgerys\n\n  * Patients aged below 18 years\n  * Patients with BMI \\\u003C 35 kg\u002Fm2\n  * Patients with psychiatric disorders\n  * Patients not willing to adhere to preoperative dietological measures\n  * Patients with contraindications against Saxenda\n  * Patients who have health insurance other than Österreichische Gesundheitskasse","ALL","18 Years",{"count":55,"type":56},72,"ESTIMATED","INTERVENTIONAL",[59],"PHASE4","The aim of the study is to investigate the effects of preoperative Saxenda (liraglutide). There are two groups, one group receives Saxena in addition to dietary measures when first seeking the operation, one group only diet. The investigator is researching how much additional preoperative weight loss is possible with the drug admitted preoperatively.",[62],"Obesity, Adolescent",[64,65,66,67,68,69,70,71],"Obesity","Bariatric surgery","metabolic surgery","liraglutide","saxenda","weight loss","surgery risk reduction","excess weight loss","NOT_YET_RECRUITING","2025-03-18",{"date":75,"type":76},"2025-03-21","ACTUAL",{"date":78,"type":56},"2025-05-01",{"date":80,"type":56},"2028-02-01",{"name":5,"class":6}]